Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02060890 · ClinicalTrials.gov registry record
Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma
A clinical trial of Adult Glioblastoma, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT02060890 is a study of Adult Glioblastoma that has completed, run by University of California, San Francisco. The registered enrollment target is 20 participants, below the 42-participant average among 14 other Adult Glioblastoma trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02060890, a study of Adult Glioblastoma, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This current study will use a new treatment approach based on each patient's tumor genomic profiling consisting of whole genome sequencing, exome analysis, and RNA sequencing as well as predictive modeling. This new treatment strategy has shown promising results in adult patients with other solid tumors.
Conditions Studied
Interventions
- OTHER specialized tumor board recommendation
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-08 |
| Est. Completion | 2017-05-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02060890
The ClinicalTrials.gov registry entry for NCT02060890 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 42-participant average among 14 other Adult Glioblastoma trials with a reported enrollment target (52% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Adult Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which specialized tumor board recommendation is the first listed.
NCT02060890 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02060890 about?
NCT02060890 is a clinical study titled "Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma". This current study will use a new treatment approach based on each patient's tumor genomic profiling consisting of whole genome sequencing, exome analysis, and RNA sequencing as well as predictive modeling. This new treatment strategy has shown promising results in adult patients with other solid tu...
What is the current status of trial NCT02060890?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2014-08. Estimated completion is 2017-05-10.
What conditions does trial NCT02060890 study?
This clinical trial studies the following conditions: Adult Glioblastoma.
What interventions are being tested in trial NCT02060890?
The interventions under investigation include: specialized tumor board recommendation (OTHER).
Who is sponsoring clinical trial NCT02060890?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02060890 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adult Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
ACTIVE NOT RECRUITING · Phase 1
-
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
ACTIVE NOT RECRUITING · Phase 1
-
Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme
COMPLETED · Phase 1
-
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
COMPLETED · Phase 1
-
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.